CD8+ T cell immunity against human respiratory syncytial virus

Vaccine

Volumn 32, Issue 46, 2014, Pages 6130-6137

  Rossey, Iebe ^a,b   Sedeyn, Koen ^a,b   De Baets, Sarah ^a,b   Schepens, Bert ^a,b   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Human respiratory syncytial virus; Immunity; T cell

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; HYBRID PROTEIN; ORAL POLIOMYELITIS VACCINE; RESPIRATORY SYNCYTIAL VIRUS INFECTION VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE ACTIVATION; VACCINATION; ANIMAL; DISEASE MODEL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; MOUSE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; LUNG; LYMPHOCYTE ACTIVATION; MICE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84907978454     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.063     Document Type: Article

References (105)

1. CDC. Respiratory Syncytial Virus Infection (RSV). 2010.
2. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140(6):543-546.
3. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
4. Falsey A.R., Walsh E.E. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000, 13(3):371-384.
5. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163(4):693-698.
6. American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-701.
7. Yewdell J.W. Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol 2010, 22(3):402-410.
8. Hammad H., Lambrecht B.N. Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses. Allergy 2011, 66(5):579-587.
9. Ruckwardt T.J., Malloy A.M., Morabito K.M., Graham B.S. Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell response. PLoS Pathog 2014, 10(2):e1003934.
10. Lukens M.V., Kruijsen D., Coenjaerts F.E., Kimpen J.L., van Bleek G.M. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J Virol 2009, 83(14):7235-7243.
11. Helft J., Manicassamy B., Guermonprez P., Hashimoto D., Silvin A., Agudo J., et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J Clin Invest 2012, 122(11):4037-4047.
12. Norton S.D., Zuckerman L., Urdahl K.B., Shefner R., Miller J., Jenkins M.K. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 1992, 149(5):1556-1561.
13. Butler N.S., Nolz J.C., Harty J.T. Immunologic considerations for generating memory CD8 T cells through vaccination. Cell Microbiol 2011, 13(7):925-933.
14. Mescher M.F., Curtsinger J.M., Agarwal P., Casey K.A., Gerner M., Hammerbeck C.D., et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006, 211:81-92.
15. de Graaff P.M., de Jong E.C., van Capel T.M., van Dijk M.E., Roholl P.J., Boes J., et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. J Immunol 2005, 175(9):5904-5911.
16. Gonzalez P.A., Prado C.E., Leiva E.D., Carreno L.J., Bueno S.M., Riedel C.A., et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci USA 2008, 105(39):14999-15004.
17. Gupta M.R., Kolli D., Molteni C., Casola A., Garofalo R.P. Paramyxovirus infection regulates T cell responses by BDCA-1+ and BDCA-3+ myeloid dendritic cells. PLoS One 2014, 9(6):pe99227.
18. Ramaswamy M., Shi L., Varga S.M., Barik S., Behlke M.A., Look D.C. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 2006, 344(2):328-339.
19. Spann K.M., Tran K.C., Chi B., Rabin R.L., Collins P.L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol 2004, 78(8):4363-4369.
20. Kotelkin A., Belyakov I.M., Yang L., Berzofsky J.A., Collins P.L., Bukreyev A. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. J Virol 2006, 80(12):5958-5967.
21. Munir S., Hillyer P., Le Nouen C., Buchholz U.J., Rabin R.L., Collins P.L., et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog 2011, 7(4):e1001336.
22. Wareing M.D., Lyon A.B., Lu B., Gerard C., Sarawar S.R. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice. J Leukoc Biol 2004, 76(4):886-895.
23. Lindell D.M., Lane T.E., Lukacs N.W. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol 2008, 38(8):2168-2179.
24. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001, 2(8):732-738.
25. Harcourt J., Alvarez R., Jones L.P., Henderson C., Anderson L.J., Tripp R.A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 2006, 176(3):1600-1608.
26. Lowin B., Hahne M., Mattmann C., Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994, 370(6491):650-652.
27. Telcian A.G., Laza-Stanca V., Edwards M.R., Harker J.A., Wang H., Bartlett N.W., et al. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J Infect Dis 2011, 203(1):85-94.
28. Chang J., Braciale T.J. Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med 2002, 8(1):54-60.
29. DiNapoli J.M., Murphy B.R., Collins P.L., Bukreyev A. Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virol J 2008, 5:105.
30. Ruckwardt T.J., Bonaparte K.L., Nason M.C., Graham B.S. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol 2009, 83(7):3019-3028.
31. Fulton R.B., Meyerholz D.K., Varga S.M. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol 2010, 185(4):2382-2392.
32. Loebbermann J., Schnoeller C., Thornton H., Durant L., Sweeney N.P., Schuijs M., et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS One 2012, 7(2):e32371.
33. Weiss K.A., Christiaansen A.F., Fulton R.B., Meyerholz D.K., Varga S.M. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol 2011, 187(6):3145-3154.
34. Sun J., Cardani A., Braciale T. Crucial role of effector T cell-derived IL-10 in regulating lung inflammation and pulmonary function during primary RSV infection. J Immunol 2010, 184.
35. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10(3):170-181.
36. Gupta M.R., Kolli D., Garofalo R.P. Differential response of BDCA-1+ and BDCA-3+ myeloid dendritic cells to respiratory syncytial virus infection. Respir Res 2013, 14(2013):71.
37. Kauth M., Grage-Griebenow E., Rohde G., Anhenn O., Wiethege A., Schultze-Werninghaus G., et al. Synergistically upregulated interleukin-10 production in cocultures of monocytes and T cells after stimulation with respiratory syncytial virus. Int Arch Allergy Immunol 2007, 142(2):116-126.
38. Sun J., Cardani A., Sharma A.K., Laubach V.E., Jack R.S., Muller W., et al. Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus. PLoS Pathog 2011, 7(8):e1002173.
39. Wilson J., Rowlands K., Rockett K., Moore C., Lockhart E., Sharland M., et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J Infect Dis 2005, 191(10):1705-1709.
40. Gentile D.A., Doyle W.J., Zeevi A., Howe-Adams J., Kapadia S., Trecki J., et al. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol 2003, 64(3):338-344.
41. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annu Rev Immunol 2007, 25:171-192.
42. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401(6754):708-712.
43. Hogan R.J., Zhong W., Usherwood E.J., Cookenham T., Roberts A.D., Woodland D.L. Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med 2001, 193(8):981-986.
44. Sathaliyawala T., Kubota M., Yudanin N., Turner D., Camp P., Thome J.J., et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 2013, 38(1):187-197.
45. Shin H., Iwasaki A. Tissue-resident memory T cells. Immunol Rev 2013, 255(1):165-181.
46. Teijaro J.R., Turner D., Pham Q., Wherry E.J., Lefrancois L., Farber D.L. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 2011, 187(11):5510-5514.
47. Deliyannis G., Kedzierska K., Lau Y.F., Zeng W., Turner S.J., Jackson D.C., et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006, 36(3):770-778.
48. Wu T., Hu Y., Lee Y.T., Bouchard K.R., Benechet A., Khanna K., et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol 2014, 95(2):215-224.
49. Turner D.L., Bickham K.L., Thome J.J., Kim C.Y., D'Ovidio F., Wherry E.J., et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol 2014, 7(3):501-510.
50. de Bree G.J., van Leeuwen E.M., Out T.A., Jansen H.M., Jonkers R.E., van Lier R.A. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med 2005, 202(10):1433-1442.
51. Blattman J.N., Antia R., Sourdive D.J., Wang X., Kaech S.M., Murali-Krishna K., et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002, 195(5):657-664.
52. Obar J.J., Khanna K.M., Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008, 28(6):859-869.
53. Bukreyev A., Belyakov I.M., Prince G.A., Yim K.C., Harris K.K., Berzofsky J.A., et al. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus. J Virol 2005, 79(15):9515-9526.
54. Lukens M.V., Claassen E.A., de Graaff P.M., van Dijk M.E., Hoogerhout P., Toebes M., et al. Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology 2006, 352(1):157-168.
55. Tasker L., Lindsay R.W., Clarke B.T., Cochrane D.W., Hou S. Infection of mice with respiratory syncytial virus during neonatal life primes for enhanced antibody and T cell responses on secondary challenge. Clin Exp Immunol 2008, 153(2):277-288.
56. Liu J., Cao S., Peppers G., Kim S.H., Graham B.S. Clonotype-specific avidity influences the dynamics and hierarchy of virus-specific regulatory and effector CD4(+) T-cell responses. Eur J Immunol 2014, 44(4):1058-1068.
57. Woodland D.L., Kohlmeier J.E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009, 9(3):153-161.
58. Kruijsen D., Bakkers M.J., van Uden N.O., Viveen M.C., van der Sluis T.C., Kimpen J.L., et al. Serum antibodies critically affect virus-specific CD4+/CD8+ T cell balance during respiratory syncytial virus infections. J Immunol 2010, 185(11):6489-6498.
59. de Bree G.J., Heidema J., van Leeuwen E.M., van Bleek G.M., Jonkers R.E., Jansen H.M., et al. Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons. J Infect Dis 2005, 191(10):1710-1718.
60. Heidema J., de Bree G.J., De Graaff P.M., van Maren W.W., Hoogerhout P., Out T.A., et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 2004, 85(Pt 8):2365-2374.
61. Mbawuike I.N., Wells J., Byrd R., Cron S.G., Glezen W.P., Piedra P.A. HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis 2001, 183(5):687-696.
62. Isaacs D., Bangham C.R., McMichael A.J. Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis. Lancet 1987, 2(8562):769-771.
63. Bont L., Versteegh J., Swelsen W.T., Heijnen C.J., Kavelaars A., Brus F., et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002, 52(3):363-367.
64. Kohlmeier J.E., Woodland D.L. Immunity to respiratory viruses. Annu Rev Immunol 2009, 27:61-82.
65. Cannon M.J., Stott E.J., Taylor G., Askonas B.A. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 1987, 62(1):133-138.
66. Cannon M.J., Openshaw P.J., Askonas B.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988, 168(3):1163-1168.
67. Graham B.S., Bunton L.A., Wright P.F., Karzon D.T. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991, 88(3):1026-1033.
68. Heidema J., Lukens M.V., van Maren W.W., van Dijk M.E., Otten H.G., van Vught A.J., et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol 2007, 179(12):8410-8417.
69. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7(5):379-390.
70. Barrios C., Brawand P., Berney M., Brandt C., Lambert P.H., Siegrist C.A. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur J Immunol 1996, 26(7):1489-1496.
71. Lukens M.V., van de Pol A.C., Coenjaerts F.E., Jansen N.J., Kamp V.M., Kimpen J.L., et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 2010, 84(5):2374-2383.
72. Welliver T.P., Garofalo R.P., Hosakote Y., Hintz K.H., Avendano L., Sanchez K., et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007, 195(8):1126-1136.
73. Hall C.B., Powell K.R., MacDonald N.E., Gala C.L., Menegus M.E., Suffin S.C., et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986, 315(2):77-81.
74. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(4):422-434.
75. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24(2):197-202.
76. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196(6):859-865.
77. Kim H.W., Leikin S.L., Arrobio J., Brandt C.D., Chanock R.M., Parrott R.H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976, 10(1):75-78.
78. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994, 68(8):5321-5325.
79. Srikiatkhachorn A., Braciale T.J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997, 186(3):421-432.
80. Aung S., Graham B.S. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J Immunol 2000, 164(7):3487-3493.
81. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci USA 2002, 99(20):13020-13025.
82. Sande C.J., Cane P.A., Nokes D.J. The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine 2014, 32(37):4726-4729.
83. Kaaijk P., Luytjes W., Rots N.Y. Vaccination against RSV: is maternal vaccination a good alternative to other approaches?. Hum Vaccine Immunother 2013, 9(6):1263-1267.
84. Zaghouani H., Hoeman C.M., Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 2009, 30(12):585-591.
85. Marr N., Wang T.I., Kam S.H., Hu Y.S., Sharma A.A., Lam A., et al. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol 2014, 192(3):948-957.
86. Agius G., Dindinaud G., Biggar R.J., Peyre R., Vaillant V., Ranger S., et al. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol 1990, 30(2):117-127.
87. Walsh E.E., Falsey A.R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol 2004, 73(2):295-299.
88. Powers D.C., Belshe R.B. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 1993, 167(3):584-592.
89. Cusi M.G., Martorelli B., Di Genova G., Terrosi C., Campoccia G., Correale P. Age related changes in T cell mediated immune response and effector memory to respiratory syncytial virus (RSV) in healthy subjects. Immunol Ageing 2010, 7:p14.
90. Gardner E.M., Murasko D.M. Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 2002, 3(5):271-290.
91. Looney R.J., Falsey A.R., Walsh E., Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis 2002, 185(5):682-685.
92. Voges B., Vallbracht S., Zimmer G., Bossow S., Neubert W.J., Richter K., et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cell Immunol 2007, 247(2):85-94.
93. Kulkarni A.B., Connors M., Firestone C.Y., Morse H.C., Murphy B.R. The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice. J Virol 1993, 67(2):1044-1049.
94. Kulkarni A.B., Collins P.L., Bacik I., Yewdell J.W., Bennink J.R., Crowe J.E., et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol 1995, 69(2):1261-1264.
95. Hsu S.C., Obeid O.E., Collins M., Iqbal M., Chargelegue D., Steward M.W. Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma. Int Immunol 1998, 10(10):1441-1447.
96. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003, 21(13-14):1478-1485.
97. Simmons C.P., Hussell T., Sparer T., Walzl G., Openshaw P., Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol 2001, 166(2):1106-1113.
98. Fan C.F., Zeng R.H., Sun C.Y., Mei X.G., Wang Y.F., Liu Y. Fusion of DsbA to the N-terminus of CTL chimeric epitope, F/M2:81-95, of respiratory syncytial virus prolongs protein- and virus-specific CTL responses in Balb/c mice. Vaccine 2005, 23(22):2869-2875.
99. Stokes K.L., Chi M.H., Sakamoto K., Newcomb D.C., Currier M.G., Huckabee M.M., et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 2011, 85(12):5782-5793.
100. Bueno S.M., Gonzalez P.A., Cautivo K.M., Mora J.E., Leiva E.D., Tobar H.E., et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA 2008, 105(52):20822-20827.
101. Cautivo K.M., Bueno S.M., Cortes C.M., Wozniak A., Riedel C.A., Kalergis A.M. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection. J Immunol 2010, 185(12):7633-7645.
102. Lee S., Stokes K.L., Currier M.G., Sakamoto K., Lukacs N.W., Celis E., et al. Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J Virol 2012, 86(23):13016-13024.
103. Lee S., Mittler R.S., Moore M.L. Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice. J Immunol 2014, 192(1):293-299.
104. De Baets S., Schepens B., Sedeyn K., Schotsaert M., Roose K., Bogaert P., et al. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J Virol 2013, 87(6):3314-3323.
105. Fonseca W., Ozawa M., Hatta M., Orozco E., Martinez M.B., Kawaoka Y. A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus. Arch Virol 2014, 159(5):1067-1077.